 | Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a... 24 KB (2,161 words) - 05:43, 7 April 2024 |
 | for long-term neurodegenerative diseases. Olaparib: In December, 2014, the EMA and US FDA approved olaparib as monotherapy (at 400 mg taken twice per... 20 KB (2,052 words) - 20:57, 21 April 2024 |
 | Fleming GF, et al. (October 2014). "Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer:... 8 KB (644 words) - 19:21, 20 December 2023 |
 | mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib. The most common adverse reactions of any grade were fatigue, anemia, nausea... 16 KB (1,214 words) - 05:39, 12 April 2024 |
 | treatments for astrocytoma and as the first-line treatment for glioblastoma. Olaparib in combination with temozolomide demonstrated substantial clinical activity... 33 KB (2,958 words) - 01:54, 19 April 2024 |
 | small-molecule drugs or monoclonal antibodies, and PARP inhibitors such as olaparib. Other therapies include hyperthermia, immunotherapy, photodynamic therapy... 70 KB (8,493 words) - 11:19, 26 February 2024 |
 | metastases due to SCLC. In a clinical trial of 50 patients, combination of olaparib and temozolomide in relapsed small-cell lung cancer yielded an overall... 53 KB (5,452 words) - 05:54, 22 April 2024 |
 | (Masoprocol) PARP inhibitor (Fuzuloparib) Niraparib +abiraterone acetate Olaparib Rucaparib) HDAC (Belinostat Entinostat Panobinostat Romidepsin Vorinostat)... 34 KB (3,112 words) - 09:16, 21 April 2024 |
 | (Masoprocol) PARP inhibitor (Fuzuloparib) Niraparib +abiraterone acetate Olaparib Rucaparib) HDAC (Belinostat Entinostat Panobinostat Romidepsin Vorinostat)... 31 KB (2,940 words) - 06:07, 28 February 2024 |
 | bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 42 KB (3,794 words) - 12:37, 9 April 2024 |
 | FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer | Myriad Genetics, Inc". investor... 22 KB (2,093 words) - 19:01, 24 February 2024 |
 | with chemotherapies (paclitaxel, docetaxel, gemcitabine, and irinotecan), olaparib, erlotinib, venetoclax, and rituximab in advanced hematological malignancies... 13 KB (1,219 words) - 16:58, 5 January 2024 |
 | bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 56 KB (5,515 words) - 20:45, 6 May 2024 |
 | bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 30 KB (2,596 words) - 18:14, 25 April 2024 |
 | for those with mutations activating the protein PIK3CA. PARP inhibitors (olaparib and talazoparib) for those with mutations that inactivate BRCA1 or BRCA2... 133 KB (14,898 words) - 19:40, 5 May 2024 |
bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 8 KB (967 words) - 07:52, 29 October 2022 |
 | bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 79 KB (6,534 words) - 05:19, 2 April 2024 |
 | clinical trials, navitoclax, and gossypol. PARP inhibitors (e.g. FDA approved olaparib, rucaparib, niraparib and talazoparib) PI3K inhibitors (e.g. perifosine... 20 KB (2,197 words) - 05:50, 29 November 2023 |
 | bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 40 KB (3,377 words) - 16:54, 30 January 2024 |
 | million. In December, the company received accelerated FDA approval for Olaparib in the treatment of women with advanced ovarian cancer who have a BRCA... 85 KB (7,811 words) - 07:01, 8 May 2024 |
 | immune checkpoint inhibitor drug pembrolizumab and PARP inhibitors, namely olaparib, rucaparib, or niraparib. Bone metastases – present in around 85% of those... 77 KB (8,858 words) - 14:12, 23 April 2024 |
 | (Masoprocol) PARP inhibitor (Fuzuloparib) Niraparib +abiraterone acetate Olaparib Rucaparib) HDAC (Belinostat Entinostat Panobinostat Romidepsin Vorinostat)... 19 KB (1,767 words) - 04:36, 20 March 2024 |
 | bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 51 KB (4,745 words) - 13:57, 29 April 2024 |
 | bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 10 KB (766 words) - 05:17, 12 April 2024 |
 | (Masoprocol) PARP inhibitor (Fuzuloparib) Niraparib +abiraterone acetate Olaparib Rucaparib) HDAC (Belinostat Entinostat Panobinostat Romidepsin Vorinostat)... 89 KB (9,767 words) - 05:10, 30 April 2024 |
 | (Masoprocol) PARP inhibitor (Fuzuloparib) Niraparib +abiraterone acetate Olaparib Rucaparib) HDAC (Belinostat Entinostat Panobinostat Romidepsin Vorinostat)... 26 KB (2,389 words) - 05:48, 7 April 2024 |
bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 20 KB (1,377 words) - 17:48, 12 March 2024 |
 | rotavirus vaccine that had $797 million in 2020 revenue; and Lynparza (olaparib), a medication for the maintenance treatment of BRCA-mutated advanced ovarian... 95 KB (9,336 words) - 11:23, 30 April 2024 |
 | platinum-sensitive recurrences is olaparib, which may improve progression-free survival but has not been shown to improve overall survival. (Olaparib, a PARP inhibitor... 194 KB (20,751 words) - 08:08, 29 April 2024 |
 | bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast... 14 KB (1,360 words) - 07:15, 5 May 2023 |